By Fineline Cube 
Genentech, a subsidiary of Swiss pharmaceutical leader Roche (SWX: ROG, OTCMKTS: RHHBY) , announced a collaboration and license agreement with US-based Repertoire Immune Medicines to co-develop T cell-targeted immune therapies for autoimmune diseases. This strategic partnership combines Repertoire’s innovative immune synapse mapping technology with Genentech’s drug development expertise.
Partnership Details
Under the agreement, Repertoire will utilize its proprietary DECODE™ platform to identify novel therapeutic targets. Genentech will then optimize these candidates and advance them into clinical-stage therapies. Repertoire is eligible to receive an upfront payment of USD 35 million, with potential milestone payments totaling up to USD 730 million across development, regulatory, and commercial stages, plus tiered royalties on future sales.-Fineline Info & Tech